Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
about
Predicting neutropenia risk in patients with cancer using electronic data.Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignanciesAssessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.Prognostic factors in patients after definitive chemoradiation using involved-field radiotherapy for esophageal cancer in a phase II study.Chemotherapy dosing in overweight and obese patients with cancer.Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment.Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer.
P2860
Q31131362-8F987E9C-6401-4DF6-9EA4-91CF6973057CQ35176826-2EE0A3D7-419A-41DD-BD8B-A36BA90EFCD4Q35748477-0A2EDFBA-F32A-4E0C-AB98-11659F52C618Q36023851-921EE1F0-DF49-4562-9659-7A4E05E32EDCQ36053032-EB6D6C62-70A9-4A6E-A9EE-7B970549ABEBQ36242803-3E4DFE29-E28C-4E50-AF6B-8B7D046E535CQ36918911-ECB448D1-955D-41E5-B9D6-F00144F0C858Q37456566-F8E2B38B-7AD8-4009-86A7-68CA69C10E32Q38121735-BF80A7AC-5C3E-45A4-87B9-11D62165978AQ38522820-6DA56518-6160-47D8-BB12-B4400DBCFBC1Q38697238-7F9772C2-1603-4594-8B89-05694466BD47Q39074316-58AACDF5-8248-4B91-BBD9-E3827368D1F1Q39698919-5F1CCBAE-0156-4430-A335-9CB5F2CA12ACQ40831081-45563D84-5F1A-44AB-84ED-FA706150D383Q43110679-077B4D6C-A591-44C0-9E68-654C342B671AQ45982211-3A56A7C0-7421-4F40-8BCB-89611BBBA391Q48291586-AE5A5F00-3E32-410D-A36E-6EBDFF99C4A3
P2860
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Predictors of reduced relative ...... for epithelial ovarian cancer.
@en
Predictors of reduced relative ...... for epithelial ovarian cancer.
@nl
type
label
Predictors of reduced relative ...... for epithelial ovarian cancer.
@en
Predictors of reduced relative ...... for epithelial ovarian cancer.
@nl
prefLabel
Predictors of reduced relative ...... for epithelial ovarian cancer.
@en
Predictors of reduced relative ...... for epithelial ovarian cancer.
@nl
P2093
P1433
P1476
Predictors of reduced relative ...... for epithelial ovarian cancer.
@en
P2093
Aaron Shafer
David C Dale
Gary H Lyman
Jeffrey Crawford
Linda Van Le
Marek S Poniewierski
Micael A Lopez
Paola A Gehrig
Rabbie K Hanna
Robin A Laskey
P356
10.1016/J.YGYNO.2012.12.017
P407
P577
2012-12-21T00:00:00Z